Aru Narendran
University of Calgary
H-index: 32
North America-Canada
Top articles of Aru Narendran
Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10
Cancer Research
2022/6/15
Halogenated xanthenes as vaccine adjuvants
2024/3/26
A cancer-associated fibroblast model to discover mechanisms of growth, survival, and treatment sensitivity in PAX3/7-FKHR fusion-positive alveolar rhabdomyosarcoma
Cancer Research
2024/3/22
Son Tran
H-Index: 0
Aru Narendran
H-Index: 19
Targeting CXCR4 via the small molecule inhibitor NMX1 as a therapeutic strategy to treat high-risk malignancies
Cancer Research
2024/3/22
Son Tran
H-Index: 0
Aru Narendran
H-Index: 19
Composition and Method for Treating Hematologic Cancers
2024/3/14
Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy
Biomedicines
2024/2/23
The developmental origins of cancer: a review of the genes expressed in embryonic cells with implications for tumorigenesis
2023/2/28
Aru Narendran
H-Index: 19
Abstract A161: A differentiation based therapeutic approach for KMT2A rearranged leukemia in infants and children
NaN
2023
Ritul Sharma
H-Index: 0
Aru Narendran
H-Index: 19
Targeting CDK9 in KMT2A-rearranged infant leukemia: evidence for activity and drug synergy with enitociclib
Blood
2023/11/28
1118. The iodinated fluorescein derivative PV-10 enhances the anti-viral activity of CD8+ T-cells by inducing STING dimerization: Implications for enhanced vaccine applications
2023/11/1
Aru Narendran
H-Index: 19
The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia
Genes
2023/10/8
Ritul Sharma
H-Index: 0
Aru Narendran
H-Index: 19
Development and validation of a 21-gene prognostic signature in neuroblastoma
Scientific Reports
2023/8/2
Establishment of at (11; 19), KMT2A Rearranged B-ALL Cell Line for Preclinical Evaluation and Novel Therapeutics Development for Refractory Infant Leukemia
Journal of Pediatric Hematology/Oncology
2023/8/1
Ritul Sharma
H-Index: 0
Aru Narendran
H-Index: 19
Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT)
2023/8/1
Son Tran
H-Index: 0
Aru Narendran
H-Index: 19
Targeting CDK9 via the small-molecule inhibitor enitociclib as a therapeutic strategy to treat MYCN-amplified rhabdomyosarcoma and neuroblastoma in children
Cancer Research
2023/4/4
Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing
Cell
2023/3/30
Xiaomeng Wu
H-Index: 8
Aru Narendran
H-Index: 19
Identification of Altered Primary Immunodeficiency-Associated Genes and Their Implications in Pediatric Cancers
Cancers
2022/1
Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma
Blood
2022/11/15
Son Tran
H-Index: 0
Ritul Sharma
H-Index: 0
Ranjan Maity
H-Index: 8
Ahmed Hamdy
H-Index: 0
Aru Narendran
H-Index: 19
Expression and Function of Modulator of Apoptosis (MOAP-1) in Blood Cancers
2022/11/7
Evan Kerek
H-Index: 6
Aru Narendran
H-Index: 19
Halogenated xanthene composition and method for treating hematologic cancers
2022/8/23
